Aclarion Publishes Shareholder Letter
Aclarion, Inc. has published its 2026 Shareholder Letter, detailing the company’s clinical and financial strategies as it progresses through its clinical trial for treating chronic low back pain. Aclarion expects an internal readout of the 300-patient CLARITY trial by the end of Q3 and plans to publicly disclose preliminary results in Q4 of 2026. The…more










